Paper Details

  1. Home
  2. Paper Details

[A case of heritable pulmonary arterial hypertension treated with long-term oral low-dose imatinib].

Author: GaoA L, GongJ N, LiJ F, YangY H

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A patient with heritable pulmonary arterial hypertension (HPAH) due to a bone morphogenetic protein 2 (BMPR2) gene mutation showed significant improvement after receiving oral imatinib for 45 months. This case report suggests that imatinib may be a feasible treatment option for HPAH.
Paper Details　
Original Abstract of the Article :
Heritable pulmonary arterial hypertension (HPAH) is a rare type of pulmonary arterial hypertension that often presents with progressive exertional dyspnea and for which there is no significant effective drug. A HPAH patient was admitted to our hospital more than three years ago, and the gene mutatio...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3760/cma.j.cn112147-20230918-00165

データ提供：米国国立医学図書館（NLM）

Heritable Pulmonary Arterial Hypertension: A Rare Case Study

Heritable pulmonary arterial hypertension (HPAH) is a rare and life-threatening condition that affects the blood vessels in the lungs. This case report describes the successful treatment of a HPAH patient with long-term oral low-dose imatinib. It's like finding a hidden oasis in the vast desert of rare diseases.

A Unique Case

The report presents a unique case of a HPAH patient with a specific gene mutation and describes the positive response to imatinib treatment. It's like discovering a new plant species that thrives in a harsh environment, offering hope for other patients with this condition.

Potential Treatment Options

This case study provides clinicians with alternative treatment options for HPAH, suggesting that imatinib could be a viable option for patients with this rare disease. It's like finding a new well in a drought-stricken land, offering a source of relief for those who need it most.

Dr.Camel's Conclusion

This case report offers a glimmer of hope for patients with HPAH, demonstrating the potential of imatinib as a treatment option. It highlights the importance of ongoing research to explore new therapies for rare diseases and improve outcomes for patients with these challenging conditions.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-12-08
Further Info :

Pubmed ID

38062692

DOI: Digital Object Identifier

10.3760/cma.j.cn112147-20230918-00165

Related Literature

Article Analysis
・Side Effects of imatinib
SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.